Publications by authors named "Song Zhaomin"
Article Synopsis
- Patients with clinically significant portal hypertension (CSPH) should be treated with non-selective beta-blockers like carvedilol to prevent liver decompensation, especially using liver stiffness (LS) measurements as a less invasive alternative to hepatic venous pressure gradient (HVPG) measurements.
- A study is planned to determine if patients with compensated cirrhosis and LS≥25 kPa can benefit from carvedilol, focusing on a randomized, double-blind, placebo-controlled trial involving 446 adults.
- The primary outcome will be the incidence of decompensation events and liver-related deaths over three years, while secondary outcomes will include various complications of portal hypertension such as
Background And Study Aims: Drug-eluting bead transarterial chemoembolization (DEB-TACE) causes serious complications, including liver abscess and biloma formation. This study aimed to investigate the frequency and risk factors of liver abscess and biloma formation after dug-eluting bead transarterial chemoembolization for unresectable intrahepatic cholangiocarcinoma (ICC).
Patients And Methods: 152 unresectable ICC patients received 241 DEB-TACE procedures from February 2018 to November 2022 were studied retrospectively.
Background: This study aimed to compare the therapeutic efficacy of transcatheter arterial chemoembolization (TACE) combined with either I seed implantation or I seed implantation and intra-tumor injection of cisplatin in treating hepatocellular carcinoma (HCC).
Methods: A total of 100 patients with HCC were analyzed. The control group (n = 50) received TACE combined with I seed implantation therapy.
Context: Radiofrequency ablation (RFA), an established and minimally invasive therapy for hepatocellular carcinoma, has become an important treatment strategy. However, tumor aggressiveness remains a common problem. The epithelial-mesenchymal transition (EMT) is thought to play an important role in this process.
View Article and Find Full Text PDFPurpose: This study aimed to retrospectively assess the outcome of interstitial iodine-125 brachytherapy for unresectable hepatocellular carcinoma (HCC).
Materials And Methods: Between February 2013 and March 2019, 57 patients with 108 unresectable HCC lesions treated with computed tomography (CT)-guided iodine-125 seed brachytherapy were retrospectively analyzed. The primary endpoint was overall survival (OS).
The feasibility of transcatheter arterial chemo-embolization (TACE) combined with intratumoral injection of cisplatin as treatment for hepatocellular carcinoma. 30 cases receiving TACE were denoted the TACE group, another 30 cases receiving TACE combined with an intratumoral multi-point injection of cisplatin were denoted the TACE/cisplatin group. Cases with partial remission/complete remission (PR/CR) were analyzed using 2 tests; alpha fetoprotein (AFP), aspartate amino transferase (AST), total bilirubin (TBIL), erythrocyte, and platelet levels were detected and the differences between two groups were analyzed using the Student's t-test; cases with complications, including intrahepatic metastasis (IM), upper gastrointestinal bleeding (UGB), and liver failure were also counted.
View Article and Find Full Text PDF[Effect of rapamycin in inducing naïve murine effector T cell convert to regulatory T cell].
Zhongguo Yi Xue Ke Xue Yuan Xue Bao
August 2008
Objective: To study the effect of rapamycin in inducing naïve murine effector T cell (Teff) convert to regulatory T cell (Treg) in vitro.
Methods: The forkhead box protein 3 (FoxP3) negative Teff were isolated and purified from the spleen and lymph node of C57 BL/6 murines aged 6-8 weeks, then Teff were cultured in three groups with mature dendritic cells (mDC), B cells, and plate coated Anti-CD3. In addition, the control wells and the test wells were prepared in each group, rapamycin were not added in the control wells but added in the test wells with concentrations of 1, 10, 50, and 100 nmol/L.